Q1 2022 Carasent ASA Earnings Call Transcript
¶ -
Hello, everyone, and welcome to today's presentation of our first-quarter report of Carasent. My name is Dennis Höjer, and I will walk through the first half of this report. And the agenda for today is, of course, to mention some highlights, the business and market updates. We will go with some financial review and the outlook.
So a quick summary of the first quarter for Carasent, we had a revenue growth of a total of 59%, of this is 22% coming from organic growth. Although 25% of our recurring growth is coming from organic growth. And we are doing some changes in our reporting structure in order to reflect our new organization [on forth]. And also, Webdoc X and the initiative to adapt by book into the Norwegian market is progressing according to plan. The acquisition of Medrave was closed in early January this year.
So a quick glance of Carasent today. As many of you probably know by now, our main focus is cloud-based proprietary medical record software solutions addressing the private health care segment within Scandinavia. We have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |